Clone TG1 validated for studying the immune checkpoint marker TIGIT in FFPE tissues
A growing number of immune checkpoints develop as targets for anticancer therapy. Cancer immunology studies have shown that cancer cells together with cells of the surrounding microenvironment generate co-inhibitory signals by upregulating the expression of components which suppress the antitumor immune response. The TIGIT pathway interacts with different inhibitory checkpoint pathways. TIGIT provides significant promise for immunotherapy, especially in combination with other immune checkpoint inhibitors.
The immunoreceptor TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a member of the poliovirus receptor (PVR) family. The expression of TIGIT has been reported on NK cells, regulatory T cells, follicular T helper cells, memory CD4+ T cells, and CD8+ T cells, but TIGIT is not expressed on B cells or naive CD4+ T cells. TIGIT acts as an inhibitory immune checkpoint on both T cells and natural killer (NK) cells by a highly complex pathway. Known ligands for TIGIT include CD155 and CD112. Moreover, the TIGIT/CD155/CD112 network also interacts with further checkpoint regulators.
In inflammation and in multiple cancer models T cells have been shown to upregulate TIGIT expression. In several types of cancer, the ligands CD155 and CD112 are also highly expressed on dendritic cells and macrophages. Moreover, TIGIT expression is highly correlated with the expression of other co-inhibitory molecules, including PD-1. In addition to directly inhibiting cytotoxic T-cell activity, TIGIT can stimulate an immunosuppressive microenvironment by influencing other immune cells: For example, TIGIT binds CD155 on the surface of dendritic cells or manipulates NK cell activity. Drugs inhibiting TIGIT activity are currently being developed.